Vera Therapeutics Inc (VERA)
37.98
+1.03
(+2.79%)
USD |
NASDAQ |
May 31, 16:00
37.98
0.00 (0.00%)
After-Hours: 20:00
Vera Therapeutics Research and Development Expense (Quarterly): 23.20M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 23.20M |
| December 31, 2023 | 20.78M |
| September 30, 2023 | 16.10M |
| June 30, 2023 | 16.23M |
| March 31, 2023 | 25.11M |
| December 31, 2022 | 26.68M |
| September 30, 2022 | 19.66M |
| June 30, 2022 | 10.11M |
| March 31, 2022 | 12.55M |
| Date | Value |
|---|---|
| December 31, 2021 | 12.75M |
| September 30, 2021 | 3.564M |
| June 30, 2021 | 3.235M |
| March 31, 2021 | 2.932M |
| December 31, 2020 | 39.84M |
| September 30, 2020 | 1.969M |
| June 30, 2020 | 1.954M |
| March 31, 2020 | 1.439M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.439M
Minimum
Mar 2020
39.84M
Maximum
Dec 2020
14.01M
Average
12.75M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 789.10M |
| Alpine Immune Sciences Inc (DELISTED) | 22.46M |
| Fate Therapeutics Inc | 32.14M |
| Mersana Therapeutics Inc | 18.69M |
| Equillium Inc | 9.743M |